AstraZeneca failed to persuade a US regulatory review panel about the benefits of its novel breast cancer medicine, throwing a hurdle in front of a key drug in the company’s pipeline. https://t.co/6oiaGq7Hcv ...

and thank you for inviting me TEDex 2025. The topic is atoms to outcomes. So as you may already know, I am a chemist.I'm a scientist in chemistry and atoms are the building blocks of any molecules or anything whatever you seen is are the fundamental particles atoms atoms combined to form molecules and molecules organized to form systems very highly complicated system whatever you see here these are the manifestations of several atoms So as you can see the complexity is not built on one day. It's a stepbyste ...

Bristol Myers Squibb posted higher first-quarter revenue boosted by its portfolio of newer treatments for heart and blood conditions. https://t.co/Bz8u2pGmz1 ...

Merck & Co. reports first-quarter sales that beat Wall Street estimates as demand ramps up for newer products https://t.co/bmsrGoTb8x ...

AstraZeneca will invest £300 million ($405 million) in UK life sciences, Prime Minister Keir Starmer told Parliament, a deal he said was enabled by the trade deal between Britain and the US https://t.co/Jam4BClCts ...

Haleon's first quarter was weaker than expected, hurt by weak demand for over-the-counter cold and flu medicines https://t.co/BQSkePFDRR ...

AstraZeneca reported rises in revenue and core earnings for the first quarter, saying growing sales of its cancer and rare-disease drugs lifted results. https://t.co/EXX8ym1TJZ ...

Italian drugmaker Angelini Pharma is exploring a potential acquisition of Catalyst Pharmaceuticals as it looks at deals to expand its footprint globally, people familiar with the matter said https://t.co/d7GF0qnHxz ...

Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer portfolio https://t.co/OKVACn0UJq ...

Eli Lilly agreed to buy closely held Ajax for as much as $2.3 billion in cash to gain promising experimental medicines for blood cancers https://t.co/Ytffetf5qn ...